REGENERON PHARMACEUTICALS (REGN) Fundamental Analysis & Valuation
NASDAQ:REGN • US75886F1075
Current stock price
761.85 USD
-15.4 (-1.98%)
At close:
761.54 USD
-0.31 (-0.04%)
After Hours:
This REGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. REGN Profitability Analysis
1.1 Basic Checks
- REGN had positive earnings in the past year.
- In the past year REGN had a positive cash flow from operations.
- Each year in the past 5 years REGN has been profitable.
- In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.11%, REGN belongs to the top of the industry, outperforming 93.81% of the companies in the same industry.
- The Return On Equity of REGN (14.41%) is better than 93.42% of its industry peers.
- REGN has a better Return On Invested Capital (9.60%) than 93.42% of its industry peers.
- REGN had an Average Return On Invested Capital over the past 3 years of 11.30%. This is significantly below the industry average of 27.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.11% | ||
| ROE | 14.41% | ||
| ROIC | 9.6% |
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
1.3 Margins
- REGN has a Profit Margin of 31.41%. This is amongst the best in the industry. REGN outperforms 94.97% of its industry peers.
- In the last couple of years the Profit Margin of REGN has declined.
- REGN's Operating Margin of 27.02% is amongst the best of the industry. REGN outperforms 94.78% of its industry peers.
- In the last couple of years the Operating Margin of REGN has declined.
- With an excellent Gross Margin value of 86.56%, REGN belongs to the best of the industry, outperforming 88.39% of the companies in the same industry.
- In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 31.41% | ||
| GM | 86.56% |
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
2. REGN Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), REGN is creating some value.
- REGN has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, REGN has less shares outstanding
- The debt/assets ratio for REGN has been reduced compared to a year ago.
2.2 Solvency
- REGN has an Altman-Z score of 7.50. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.50, REGN is in the better half of the industry, outperforming 78.72% of the companies in the same industry.
- The Debt to FCF ratio of REGN is 0.72, which is an excellent value as it means it would take REGN, only 0.72 years of fcf income to pay off all of its debts.
- REGN's Debt to FCF ratio of 0.72 is amongst the best of the industry. REGN outperforms 94.97% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 61.70% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 7.5 |
ROIC/WACC1.05
WACC9.1%
2.3 Liquidity
- A Current Ratio of 4.13 indicates that REGN has no problem at all paying its short term obligations.
- The Current ratio of REGN (4.13) is comparable to the rest of the industry.
- A Quick Ratio of 3.56 indicates that REGN has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.56, REGN perfoms like the industry average, outperforming 45.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.13 | ||
| Quick Ratio | 3.56 |
3. REGN Growth Analysis
3.1 Past
- REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
- The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
- Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 0.99% in the last year.
- The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
3.2 Future
- The Earnings Per Share is expected to grow by 10.96% on average over the next years. This is quite good.
- The Revenue is expected to grow by 8.10% on average over the next years. This is quite good.
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue Next Year10.7%
Revenue Next 2Y10.56%
Revenue Next 3Y9.89%
Revenue Next 5Y8.1%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. REGN Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 17.17, REGN is valued on the expensive side.
- REGN's Price/Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 94.20% of the companies in the same industry.
- REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.17.
- A Price/Forward Earnings ratio of 16.30 indicates a correct valuation of REGN.
- 95.16% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
- REGN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 16.3 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.36% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 95.16% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.39 | ||
| EV/EBITDA | 12.09 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- REGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.21
PEG (5Y)2.45
EPS Next 2Y11.15%
EPS Next 3Y11.8%
5. REGN Dividend Analysis
5.1 Amount
- REGN has a yearly dividend return of 0.51%, which is pretty low.
- REGN's Dividend Yield is rather good when compared to the industry average which is at 1.11. REGN pays more dividend than 98.45% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.89, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.51% |
5.2 History
- REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 8.22% of the earnings are spent on dividend by REGN. This is a low number and sustainable payout ratio.
DP8.22%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
REGN Fundamentals: All Metrics, Ratios and Statistics
761.85
-15.4 (-1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30 2026-01-30/bmo
Earnings (Next)04-29 2026-04-29
Inst Owners90.78%
Inst Owner Change0%
Ins Owners1.94%
Ins Owner Change3.34%
Market Cap80.54B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.58
Price Target880.4 (15.56%)
Short Float %2.41%
Short Ratio3.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.51% |
Yearly Dividend3.44
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-20 2026-02-20 (0.94)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)0.69%
PT rev (3m)8.93%
EPS NQ rev (1m)-0.76%
EPS NQ rev (3m)-13.09%
EPS NY rev (1m)0%
EPS NY rev (3m)1.5%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)3.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 16.3 | ||
| P/S | 5.62 | ||
| P/FCF | 21.39 | ||
| P/OCF | 16.18 | ||
| P/B | 2.58 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | 12.09 |
EPS(TTM)44.38
EY5.83%
EPS(NY)46.75
Fwd EY6.14%
FCF(TTM)35.61
FCFY4.67%
OCF(TTM)47.1
OCFY6.18%
SpS135.67
BVpS295.66
TBVpS283.76
PEG (NY)3.21
PEG (5Y)2.45
Graham Number543.35
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.11% | ||
| ROE | 14.41% | ||
| ROCE | 10.71% | ||
| ROIC | 9.6% | ||
| ROICexc | 29.34% | ||
| ROICexgc | 32.83% | ||
| OM | 27.02% | ||
| PM (TTM) | 31.41% | ||
| GM | 86.56% | ||
| FCFM | 26.25% |
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
ROICexc(3y)21.75%
ROICexc(5y)28.65%
ROICexgc(3y)23.56%
ROICexgc(5y)30%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 223.23% | ||
| Cap/Sales | 8.46% | ||
| Interest Coverage | 93.15 | ||
| Cash Conversion | 112.68% | ||
| Profit Quality | 83.58% | ||
| Current Ratio | 4.13 | ||
| Quick Ratio | 3.56 | ||
| Altman-Z | 7.5 |
F-Score5
WACC9.1%
ROIC/WACC1.05
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year10.7%
Revenue Next 2Y10.56%
Revenue Next 3Y9.89%
Revenue Next 5Y8.1%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year13.49%
EBIT Next 3Y14.31%
EBIT Next 5Y10.45%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%
REGENERON PHARMACEUTICALS / REGN Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
What is the profitability of REGN stock?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for REGN stock?
The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (REGN) is 17.17 and the Price/Book (PB) ratio is 2.58.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to grow by 5.35% in the next year.